<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Market News &#38; Stocks to Watch from StraightStocks &#187; Jeffrey M. Ostrove;</title>
	<atom:link href="http://www.straightstocks.com/tag/jeffrey-m-ostrove/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.straightstocks.com</link>
	<description>Leading Stock Market News, Opinions and Commentary</description>
	<lastBuildDate>Sat, 20 Mar 2010 20:12:17 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.9.2</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Cell Genesys, Inc. (CEGE) &#8211; Ceregene Inc. Secures $5.4 Million in Funding for Phase II Studies</title>
		<link>http://www.straightstocks.com/small-cap-and-micro-cap-stocks/cell-genesys-inc-cege-ceregene-inc-secures-54-million-in-funding-for-phase-ii-studies/</link>
		<comments>http://www.straightstocks.com/small-cap-and-micro-cap-stocks/cell-genesys-inc-cege-ceregene-inc-secures-54-million-in-funding-for-phase-ii-studies/#comments</comments>
		<pubDate>Tue, 04 Nov 2008 22:05:02 +0000</pubDate>
		<dc:creator>QualityStocks</dc:creator>
				<category><![CDATA[Small & Micro Cap]]></category>
		<category><![CDATA[ALS]]></category>
		<category><![CDATA[Alta Partners;]]></category>
		<category><![CDATA[Alzheimer's]]></category>
		<category><![CDATA[Alzheimer's disease]]></category>
		<category><![CDATA[California]]></category>
		<category><![CDATA[California Technology Partners;]]></category>
		<category><![CDATA[Cell Genesys Inc.]]></category>
		<category><![CDATA[CERE-100;]]></category>
		<category><![CDATA[CERE-110;]]></category>
		<category><![CDATA[Ceregene Inc.;]]></category>
		<category><![CDATA[gene delivery;]]></category>
		<category><![CDATA[Investor Growth Capital;]]></category>
		<category><![CDATA[Jeffrey M. Ostrove;]]></category>
		<category><![CDATA[Lou Gehrig]]></category>
		<category><![CDATA[MPM Capital;]]></category>
		<category><![CDATA[National Institute of Aging;]]></category>
		<category><![CDATA[National Institute of Health]]></category>
		<category><![CDATA[neurodegenerative disorders;]]></category>
		<category><![CDATA[Paul Aisen;]]></category>
		<category><![CDATA[San Diego]]></category>
		<category><![CDATA[therapy for Alzheimer s disease;]]></category>
		<category><![CDATA[treatment of Alzheimer's disease;]]></category>
		<category><![CDATA[United States]]></category>
		<category><![CDATA[University of California]]></category>
		<category><![CDATA[USD]]></category>

		<guid isPermaLink="false">http://Blog.QualityStocks.net/?p=13257</guid>
		<description><![CDATA[Ceregene Inc. concentrates on the delivery of nervous system growth factors to treat neurodegenerative disorders using gene delivery. Specifically, the company created CERE-110 for the treatment of Alzheimer’s disease, which affects millions of people in the United States. 
The company today announced the University of California, San Diego, has received a $5.4 million grant from [...]]]></description>
		<wfw:commentRss>http://www.straightstocks.com/small-cap-and-micro-cap-stocks/cell-genesys-inc-cege-ceregene-inc-secures-54-million-in-funding-for-phase-ii-studies/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
